Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04791826 · ClinicalTrials.gov registry record · NA
Electronic Alerts for Heart Failure Prevention in Diabetes
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 1,524
- Enrollment target
NCT04791826: Completed NA study, sponsored by University of Texas Southwestern Medical Center.
NCT04791826 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1,524 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04791826, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,524 participants
- Enrollment target
Study Summary
Type 2 diabetes mellitus (T2DM) is an independent risk factor for heart failure (HF) and is associated with significant morbidity and mortality. Recent therapeutic advances in pharmacotherapies, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown to be beneficial in preventing HF among patients with T2DM. However, despite widely available risk prediction and stratification tools and evidence-based practice guidelines, SGLT-2i medications are under-prescribed in the United States. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a clinical decision support (CDS) tool to alert providers and improve HF risk stratification in patients with T2DM.
Primary Outcome
Prescription rate of SGLT-2i medication (no. of patients prescribed SGLT2 / no. of eligible patients)
Interventions
- BEHAVIORAL On-screen electronic alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,524 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2024-05-07 |
| Phase | NA |
What the finished NCT04791826 record still lists
NCT04791826 is an interventional study that assigns participants to a tested intervention. Its 1,524 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which On-screen electronic alert is the first listed.
NCT04791826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04791826 about?
NCT04791826 is a clinical study titled "Electronic Alerts for Heart Failure Prevention in Diabetes". Type 2 diabetes mellitus (T2DM) is an independent risk factor for heart failure (HF) and is associated with significant morbidity and mortality. Recent therapeutic advances in pharmacotherapies, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown to be beneficial in preventing HF ...
What is the current status of trial NCT04791826?
This trial is currently completed. It is a NA study. The enrollment target is 1,524 participants. The study started on 2021-03-25. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT04791826?
The interventions under investigation include: On-screen electronic alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT04791826?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04791826's enrollment target sits among peer trials
1,524 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI